{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:17:43Z","timestamp":1789449463565,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T00:00:00Z","timestamp":1484006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40266-016-0434-6","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T05:12:18Z","timestamp":1484025138000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified?"],"prefix":"10.1007","volume":"34","author":[{"given":"Andrew H.","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo P.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,10]]},"reference":[{"issue":"9503","key":"434_CR1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112\u20137.","journal-title":"Lancet."},{"key":"434_CR2","doi-asserted-by":"crossref","first-page":"b158","DOI":"10.1136\/bmj.b158","volume":"338","author":"A Burns","year":"2009","unstructured":"Burns A, Iliffe S. Alzheimer\u2019s disease. BMJ. 2009;338:b158.","journal-title":"BMJ."},{"key":"434_CR3","unstructured":"AIHW. Dementia in Australia. Cat. no. AGE 70. Canberra (ACT): Australian Institute of Health and Welfare; 2012."},{"key":"434_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1192\/bjp.157.1.72","volume":"157","author":"A Burns","year":"1990","unstructured":"Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer\u2019s disease. Br J Psychiatry. 1990;157:72\u201394.","journal-title":"Br J Psychiatry."},{"issue":"6","key":"434_CR5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JGP.0b013e3181ec897f","volume":"19","author":"SE Starkstein","year":"2011","unstructured":"Starkstein SE, Dragovic M, Jorge R, et al. Diagnostic criteria for depression in Alzheimer disease: a study of symptom patterns using latent class analysis. Am J Geriatr Psychiatry. 2011;19(6):551\u20138.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"2","key":"434_CR6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0165-0327(99)00057-9","volume":"59","author":"C Ballard","year":"2000","unstructured":"Ballard C, Neill D, O\u2019Brien J, et al. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord. 2000;59(2):97\u2013106.","journal-title":"J Affect Disord."},{"issue":"5","key":"434_CR7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1176\/appi.ajp.161.5.843","volume":"161","author":"CG Ballard","year":"2004","unstructured":"Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry. 2004;161(5):843\u20139.","journal-title":"Am J Psychiatry."},{"issue":"5\u20136","key":"434_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000369882","volume":"39","author":"T Chakrabarty","year":"2015","unstructured":"Chakrabarty T, Sepehry AA, Jacova C, Hsiung GY. The prevalence of depressive symptoms in frontotemporal dementia: a meta-analysis. Dement Geriatr Cogn Disord. 2015;39(5\u20136):257\u201371.","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"3","key":"434_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S1041610204000468","volume":"16","author":"W Black","year":"2004","unstructured":"Black W, Almeida OP. A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. Int Psychogeriatr. 2004;16(3):295\u2013315.","journal-title":"Int Psychogeriatr."},{"issue":"4","key":"434_CR10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/JGP.0b013e3181e898d0","volume":"19","author":"MA Rapp","year":"2011","unstructured":"Rapp MA, Schnaider-Beeri M, Wysocki M, et al. Cognitive decline in patients with dementia as a function of depression. Am J Geriatr Psychiatry. 2011;19(4):357\u201363.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"2","key":"434_CR11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.maturitas.2014.04.005","volume":"79","author":"AH Ford","year":"2014","unstructured":"Ford AH. Neuropsychiatric aspects of dementia. Maturitas. 2014;79(2):209\u201315.","journal-title":"Maturitas."},{"issue":"6","key":"434_CR12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/153331750502000611","volume":"20","author":"DC Steffens","year":"2005","unstructured":"Steffens DC, Maytan M, Helms MJ, Plassman BL. Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. Am J Alzheimers Dis Other Demen. 2005;20(6):367\u201373.","journal-title":"Am J Alzheimers Dis Other Demen."},{"issue":"1","key":"434_CR13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.0b013e3181e62138","volume":"75","author":"JS Saczynski","year":"2010","unstructured":"Saczynski JS, Beiser A, Seshadri S, et al. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010;75(1):35\u201341.","journal-title":"Neurology."},{"issue":"7","key":"434_CR14","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1742-1241.2009.02079.x","volume":"63","author":"A Klugman","year":"2009","unstructured":"Klugman A, Marshall J, Tabet N. Impact of cerebrovascular pathology on behavioural and neuropsychiatric symptoms in patients with Alzheimer\u2019s dementia: findings from a retrospective, naturalistic study. Int J Clin Pract. 2009;63(7):1024\u201330.","journal-title":"Int J Clin Pract."},{"issue":"4","key":"434_CR15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopsych.2004.11.035","volume":"57","author":"VA Holthoff","year":"2005","unstructured":"Holthoff VA, Beuthien-Baumann B, Kalbe E, et al. Regional cerebral metabolism in early Alzheimer\u2019s disease with clinically significant apathy or depression. Biol Psychiatry. 2005;57(4):412\u201321.","journal-title":"Biol Psychiatry."},{"issue":"4","key":"434_CR16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1192\/bjp.bp.114.148130","volume":"207","author":"V Orgeta","year":"2015","unstructured":"Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293\u20138.","journal-title":"Br J Psychiatry."},{"issue":"11","key":"434_CR17","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1176\/appi.ajp.162.11.1996","volume":"162","author":"G Livingston","year":"2005","unstructured":"Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996\u20132021.","journal-title":"Am J Psychiatry."},{"issue":"7","key":"434_CR18","doi-asserted-by":"crossref","first-page":"e005623","DOI":"10.1136\/bmjopen-2014-005623","volume":"4","author":"OP Almeida","year":"2014","unstructured":"Almeida OP, MacLeod C, Flicker L, et al. RAndomised controlled trial to imProve depressIon and the quality of life of people with Dementia using cognitive bias modification: RAPID study protocol. BMJ Open. 2014;4(7):e005623.","journal-title":"BMJ Open."},{"issue":"4","key":"434_CR19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1532-5415.2011.03355.x","volume":"59","author":"JC Nelson","year":"2011","unstructured":"Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577\u201385.","journal-title":"J Am Geriatr Soc."},{"key":"434_CR20","first-page":"CD003944","volume":"4","author":"J Bains","year":"2002","unstructured":"Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2002;4:CD003944.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"434_CR21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/070674370705200407","volume":"52","author":"S Thompson","year":"2007","unstructured":"Thompson S, Herrmann N, Rapoport MJ, Lanctot KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer\u2019s disease: a metaanalysis. Can J Psychiatry. 2007;52(4):248\u201355.","journal-title":"Can J Psychiatry."},{"issue":"9789","key":"434_CR22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(11)60830-1","volume":"378","author":"S Banerjee","year":"2011","unstructured":"Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403\u201311.","journal-title":"Lancet."},{"issue":"4\u20135","key":"434_CR23","first-page":"131","volume":"47","author":"N Mokhber","year":"2014","unstructured":"Mokhber N, Abdollahian E, Soltanifar A, et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry. 2014;47(4\u20135):131\u201340.","journal-title":"Pharmacopsychiatry."},{"issue":"7","key":"434_CR24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391.","journal-title":"JAMA."},{"issue":"5","key":"434_CR25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","volume":"173","author":"AK Leonpacher","year":"2016","unstructured":"Leonpacher AK, Peters ME, Drye LT, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: evidence from the CitAD Study. Am J Psychiatry. 2016;173(5):473\u201380.","journal-title":"Am J Psychiatry."},{"issue":"2","key":"434_CR26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11920-015-0656-z","volume":"18","author":"JM Wilkins","year":"2016","unstructured":"Wilkins JM, Forester BP. Update on SSRI treatment for neuropsychiatric symptoms of dementia. Curr Psychiatry Rep. 2016;18(2):14.","journal-title":"Curr Psychiatry Rep."},{"key":"434_CR27","doi-asserted-by":"crossref","first-page":"e1566","DOI":"10.1136\/bmj.e1566","volume":"344","author":"S Bergh","year":"2012","unstructured":"Bergh S, Selbaek G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012;344:e1566.","journal-title":"BMJ."},{"key":"434_CR28","first-page":"CD005593","volume":"1","author":"J Birks","year":"2006","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;1:CD005593.","journal-title":"Cochrane Database Syst Rev"},{"key":"434_CR29","first-page":"CD003154","volume":"2","author":"R McShane","year":"2006","unstructured":"McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;2:CD003154.","journal-title":"Cochrane Database Syst Rev"},{"key":"434_CR30","first-page":"CD001190","volume":"1","author":"J Birks","year":"2006","unstructured":"Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;1:CD001190.","journal-title":"Cochrane Database Syst Rev"},{"key":"434_CR31","first-page":"CD001191","volume":"9","author":"JS Birks","year":"2015","unstructured":"Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2015;9:CD001191.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"434_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","volume":"19","author":"SI Finkel","year":"2004","unstructured":"Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer\u2019s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19(1):9\u201318.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"7","key":"434_CR33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/01.JGP.0000221293.91312.d3","volume":"14","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, McRae T, Zhang R, Donepezil-Sertraline Study G. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14(7):605\u201312.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"5","key":"434_CR34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1041610209990354","volume":"21","author":"J Rodda","year":"2009","unstructured":"Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5):813\u201324.","journal-title":"Int Psychogeriatr."},{"issue":"2","key":"434_CR35","first-page":"125","volume":"24","author":"R Schmidt","year":"2010","unstructured":"Schmidt R, Baumhackl U, Berek K, et al. Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria. Neuropsychiatr. 2010;24(2):125\u201331.","journal-title":"Neuropsychiatr."},{"issue":"1","key":"434_CR36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000330032","volume":"1","author":"IA Lockhart","year":"2011","unstructured":"Lockhart IA, Orme ME, Mitchell SA. The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer\u2019s disease: systematic review and meta-analysis. Dement Geriatr Cogn Dis Extra. 2011;1(1):212\u201327.","journal-title":"Dement Geriatr Cogn Dis Extra."},{"issue":"1","key":"434_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/01.wnl.0000223333.42368.f1","volume":"67","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67(1):57\u201363.","journal-title":"Neurology."},{"issue":"5","key":"434_CR38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345.","journal-title":"Ther Adv Chronic Dis."},{"key":"434_CR39","first-page":"CD000464","volume":"3","author":"V Kirchner","year":"2001","unstructured":"Kirchner V, Kelly CA, Harvey RJ. Thioridazine for dementia. Cochrane Database Syst Rev. 2001;3:CD000464.","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"434_CR40","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med. 2006;355(15):1525\u201338.","journal-title":"N Engl J Med."},{"issue":"7","key":"434_CR41","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","volume":"165","author":"DL Sultzer","year":"2008","unstructured":"Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer\u2019s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844\u201354.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"434_CR42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2006.04.020","volume":"30","author":"T Terao","year":"2006","unstructured":"Terao T, Nakano H, Inoue Y, et al. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1125\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"1","key":"434_CR43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1399-5618.2009.00788.x","volume":"12","author":"LV Kessing","year":"2010","unstructured":"Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12(1):87\u201394.","journal-title":"Bipolar Disord."},{"issue":"6","key":"434_CR44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","volume":"70","author":"H Hampel","year":"2009","unstructured":"Hampel H, Ewers M, Burger K, et al. Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70(6):922\u201331.","journal-title":"J Clin Psychiatry."},{"key":"434_CR45","first-page":"CD003945","volume":"3","author":"E Lonergan","year":"2009","unstructured":"Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;3:CD003945.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"434_CR46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0924-9338(96)80303-8","volume":"10","author":"M Lemke","year":"1995","unstructured":"Lemke M. Effect of carbamazepine on agitation and emotional lability associated with severe dementia. Eur Psychiatry. 1995;10(5):259\u201362.","journal-title":"Eur Psychiatry."},{"issue":"1","key":"434_CR47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.155.1.54","volume":"155","author":"PN Tariot","year":"1998","unstructured":"Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54\u201361.","journal-title":"Am J Psychiatry."},{"issue":"1","key":"434_CR48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/psyg.12085","volume":"15","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Gen K. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer\u2019s disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics. 2015;15(1):32\u20137.","journal-title":"Psychogeriatrics."},{"issue":"6","key":"434_CR49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40263-016-0342-7","volume":"30","author":"BS Husebo","year":"2016","unstructured":"Husebo BS, Achterberg W, Flo E. Identifying and managing pain in people with Alzheimer\u2019s disease and other types of dementia: a systematic review. CNS Drugs. 2016;30(6):481\u201397.","journal-title":"CNS Drugs."},{"issue":"8","key":"434_CR50","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/gps.4063","volume":"29","author":"BS Husebo","year":"2014","unstructured":"Husebo BS, Ballard C, Fritze F, et al. Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial. Int J Geriatr Psychiatry. 2014;29(8):828\u201336.","journal-title":"Int J Geriatr Psychiatry."},{"key":"434_CR51","doi-asserted-by":"crossref","first-page":"d4065","DOI":"10.1136\/bmj.d4065","volume":"343","author":"BS Husebo","year":"2011","unstructured":"Husebo BS, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065.","journal-title":"BMJ."},{"issue":"20","key":"434_CR52","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","volume":"289","author":"SA Shumaker","year":"2003","unstructured":"Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women\u2019s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651\u201362.","journal-title":"JAMA."},{"key":"434_CR53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1745-6215-15-312","volume":"15","author":"OP Almeida","year":"2014","unstructured":"Almeida OP, Marsh K, Flicker L, et al. Reducing depression during the menopausal transition: study protocol for a randomised controlled trial. Trials. 2014;15:312.","journal-title":"Trials."},{"issue":"1","key":"434_CR54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JGP.0b013e3181beaaf4","volume":"18","author":"A Valen-Sendstad","year":"2010","unstructured":"Valen-Sendstad A, Engedal K, Stray-Pedersen B, et al. Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. Am J Geriatr Psychiatry. 2010;18(1):11\u201320.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"5733","key":"434_CR55","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K Santacruz","year":"2005","unstructured":"Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476\u201381.","journal-title":"Science."},{"issue":"12","key":"434_CR56","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1074\/jbc.271.12.6839","volume":"271","author":"T Tomiyama","year":"1996","unstructured":"Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem. 1996;271(12):6839\u201344.","journal-title":"J Biol Chem."},{"issue":"5","key":"434_CR57","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","volume":"28","author":"DW Molloy","year":"2013","unstructured":"Molloy DW, Standish TI, Zhou Q, et al. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer\u2019s disease: the DARAD trial. Int J Geriatr Psychiatry. 2013;28(5):463\u201370.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"2","key":"434_CR58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2042098611400332","volume":"2","author":"C Beer","year":"2011","unstructured":"Beer C, Loh PK, Peng YG, et al. A pilot randomized controlled trial of deprescribing. Ther Adv Drug Saf. 2011;2(2):37\u201343.","journal-title":"Ther Adv Drug Saf."},{"issue":"1\u20132","key":"434_CR59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jns.2009.02.346","volume":"283","author":"AD Korczyn","year":"2009","unstructured":"Korczyn AD, Halperin I. Depression and dementia. J Neurol Sci. 2009;283(1\u20132):139\u201342.","journal-title":"J Neurol Sci."},{"issue":"2","key":"434_CR60","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","volume":"18","author":"PB Rosenberg","year":"2010","unstructured":"Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136\u201345.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"7","key":"434_CR61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.60.7.737","volume":"60","author":"CG Lyketsos","year":"2003","unstructured":"Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737\u201346.","journal-title":"Arch Gen Psychiatry."},{"issue":"1","key":"434_CR62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00019442-200002000-00009","volume":"8","author":"C Magai","year":"2000","unstructured":"Magai C, Kennedy G, Cohen CI, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer\u2019s disease. Am J Geriatr Psychiatry. 2000;8(1):66\u201374.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"1","key":"434_CR63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000102570","volume":"24","author":"UG Vasconcelos Cunha de","year":"2007","unstructured":"de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord. 2007;24(1):36\u201341.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"434_CR64","unstructured":"National Institute for Health and Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care. National Institute for Health and Clinical Excellence Clinical Guideline 42. 2006."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-016-0434-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:46:10Z","timestamp":1498376770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-016-0434-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,10]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1007\/s40266-016-0434-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,10]]}}}